HVEM (14-39)

HVEM (14-39) is a B- and T-lymphocyte attenuator (BTLA) peptide inhibitor. HVEM (14-39) can be combined with BTLA with a KD of 0.102 μM. HVEM (14-39) enhances the activation and proliferation of T cells by regulating the expression of BTLA and HVEM in T cells, and promotes the transformation of cells into effector memory T cells. HVEM (14-39) inhibits tumor cell proliferation and promotes late apoptosis. HVEM (14-39) has immunomodulatory effects and can be used in the study of cancer[1].

12352209

Apoptosis

Apoptosis

Cancer; Inflammation/Immunology

O=C(C)N[C@H](C(N[C@H](C(N[C@H](C(N1C(C(NC(C(N[C@H](C(N[C@H](C(N2[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]3C)=O)CCC(O)=O)=O)CCCCN)=O)C(C)C)=O)CCCNC(N)=N)=O)CC4=CC=C(O)C=C4)=O)=O)CCC2)=O)CO)=O)CSSC[C@H](NC5=O)C(N[C@H](C(N6[C@H](C(N)=O)CCC6)=O)CCC(O)=O)=O)=O)CCCCN)=O)CCC1)=O)CSSC[C@H](NC3=O)C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H]5C(C)C)=O)[C@@H](C)O)=O)=O)[C@@H](C)O)=O)CC(C)C)=O)CCC(O)=O)=O)=O)=O)CO)=O)CCC(O)=O

C115H182N32O40S4

2781.13

[1]Wojciechowicz K, et al. Targeting BTLA with the peptide inhibitor HVEM (14-39) - A new way to restore the activity of T cells in melanoma. Biomed Pharmacother. 2024 Jun;175:116675.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10851/

Peptides

No Development Reported